{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:56:05Z","timestamp":1791251765259,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,7,10]],"date-time":"2007-07-10T00:00:00Z","timestamp":1184025600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In order to accurately distinguish gaps of varying length in drug treatment for chronic conditions from discontinuation without resuming therapy, short-term observation does not suffice. Thus, the use of inhalation corticosteroids (ICS) in the long-term, during a ten-year period is investigated. To describe medication use as a continuum, taking into account the timeliness and consistency of refilling, a Markov model is proposed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients, that filled at least one prescription in 1993, were selected from the PHARMO medical record linkage system (RLS) containing &gt;95% prescription dispensings per patient originating from community pharmacy records of 6 medium-sized cities in the Netherlands.<\/jats:p>\n            <jats:p>The probabilities of continuous use, the refilling of at least one ICS prescription in each year of follow-up, and medication free periods were assessed by Markov analysis. Stratified analysis according to new use was performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The transition probabilities of the refilling of at least one ICS prescription in the subsequent year of follow-up, were assessed for each year of follow-up and for the total study period.<\/jats:p>\n            <jats:p>The change of transition probabilities in time was evaluated, e.g. the probability of continuing ICS use of starters in the first two years (51%) of follow-up increased to more than 70% in the following years. The probabilities of different patterns of medication use were assessed: continuous use (7.7%), cumulative medication gaps (1\u20138 years 69.1%) and discontinuing (23.2%) during ten-year follow-up for new users. New users had lower probability of continuous use (7.7%) and more variability in ICS refill patterns than previous users (56%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In addition to well-established methods in epidemiology to ascertain compliance and persistence, a Markov model could be useful to further specify the variety of possible patterns of medication use within the continuum of adherence. This Markov model describes variation in behaviour and patterns of ICS use and could also be useful to investigate continuous use of other drugs applied in chronic diseases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6963-7-106","type":"journal-article","created":{"date-parts":[[2007,7,10]],"date-time":"2007-07-10T06:14:23Z","timestamp":1184048063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Distinguishing patterns in the dynamics of long-term medication use by Markov analysis: beyond persistence"],"prefix":"10.1186","volume":"7","author":[{"given":"Tanja T","family":"Menckeberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana V","family":"Belitser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel L","family":"Bouvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelon","family":"Bracke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem J","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan AM","family":"Raaijmakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert GM","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,7,10]]},"reference":[{"key":"447_CR1","unstructured":"Diet, nutrition and the prevention of chronic diseases. 2003, Geneva, World Health Organisation, 150."},{"key":"447_CR2","unstructured":"WHO strategy for prevention and control of chronic respiratory diseases. 2002, Geneva, World Health Organisation"},{"key":"447_CR3","volume-title":"Global Initiative for Asthma: Global strategy for asthma management and prevention","author":"GINA","year":"2005","unstructured":"GINA: Global Initiative for Asthma: Global strategy for asthma management and prevention. 2005, Bethesda, MD, National Institutes of Health, National Heart Lung and Blood Institute"},{"key":"447_CR4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/thx.2004.023754","volume":"59","author":"H Powell","year":"2004","unstructured":"Powell H, Gibson PG: Initial starting dose of inhaled corticosteroids in adults with asthma: a systematic review. Thorax. 2004, 59: 1041-1045. 10.1136\/thx.2004.023754.","journal-title":"Thorax"},{"key":"447_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/00063198-200401000-00004","volume":"10","author":"LP Boulet","year":"2004","unstructured":"Boulet LP: Once-daily inhaled corticosteroids for the treatment of asthma. Curr Opin Pulm Med. 2004, 10: 15-21. 10.1097\/00063198-200401000-00004.","journal-title":"Curr Opin Pulm Med"},{"key":"447_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T: Adherence to medication. N Engl J Med. 2005, 353: 487-497. 10.1056\/NEJMra050100.","journal-title":"N Engl J Med"},{"key":"447_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0954-6111(99)90260-3","volume":"93","author":"GM Cochrane","year":"1999","unstructured":"Cochrane GM, Horne R, Chanez P: Compliance in asthma. Respir Med. 1999, 93: 763-769. 10.1016\/S0954-6111(99)90260-3.","journal-title":"Respir Med"},{"key":"447_CR8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1378\/chest.117.2.542","volume":"117","author":"MG Cochrane","year":"2000","unstructured":"Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH: Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest. 2000, 117: 542-550. 10.1378\/chest.117.2.542.","journal-title":"Chest"},{"key":"447_CR9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.rmed.2004.01.014","volume":"98","author":"NS Breekveldt-Postma","year":"2004","unstructured":"Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raaijmakers JA, Herings RM: Persistence with inhaled corticosteroid therapy in daily practice. Respir Med. 2004, 98: 752-759. 10.1016\/j.rmed.2004.01.014.","journal-title":"Respir Med"},{"key":"447_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000175041","volume":"80 Suppl 1","author":"P Rudd","year":"1992","unstructured":"Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D: Issues in patient compliance: the search for therapeutic sufficiency. Cardiology. 1992, 80 Suppl 1: 2-10.","journal-title":"Cardiology"},{"key":"447_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/ajh\/1.3.309","volume":"1","author":"P Rudd","year":"1988","unstructured":"Rudd P, Byyny RL, Zachary V, LoVerde ME, Mitchell WD, Titus C, Marshall G: Pill count measures of compliance in a drug trial: variability and suitability. Am J Hypertens. 1988, 1: 309-312.","journal-title":"Am J Hypertens"},{"key":"447_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","volume":"50","author":"JF Steiner","year":"1997","unstructured":"Steiner JF, Prochazka AV: The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997, 50: 105-116. 10.1016\/S0895-4356(96)00268-5.","journal-title":"J Clin Epidemiol"},{"key":"447_CR13","first-page":"449","volume":"11","author":"R Sikka","year":"2005","unstructured":"Sikka R, Xia F, Aubert RE: Estimating medication persistency using administrative claims data. Am J Manag Care. 2005, 11: 449-457.","journal-title":"Am J Manag Care"},{"key":"447_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jama.1997.03540350037030","volume":"277","author":"JG Donahue","year":"1997","unstructured":"Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R: Inhaled steroids and the risk of hospitalization for asthma. Jama. 1997, 277: 887-891. 10.1001\/jama.277.11.887.","journal-title":"Jama"},{"key":"447_CR15","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1136\/thorax.57.10.880","volume":"57","author":"S Suissa","year":"2002","unstructured":"Suissa S, Ernst P, Kezouh A: Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002, 57: 880-884. 10.1136\/thorax.57.10.880.","journal-title":"Thorax"},{"key":"447_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/thorax.57.8.683","volume":"57","author":"SF Lanes","year":"2002","unstructured":"Lanes SF, Garcia Rodriguez LA, Huerta C: Respiratory medications and risk of asthma death. Thorax. 2002, 57: 683-686. 10.1136\/thorax.57.8.683.","journal-title":"Thorax"},{"key":"447_CR17","first-page":"251","volume":"39","author":"E Degli Esposti","year":"2001","unstructured":"Degli Esposti E, Sturani A, Degli Esposti L, Macini PL, Falasca P, Valpiani G, Buda S: Pharmacoutilization of antihypertensive drugs: a model of analysis. Int J Clin Pharmacol Ther. 2001, 39: 251-258.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"447_CR18","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.1990.03440120075040","volume":"263","author":"BM Psaty","year":"1990","unstructured":"Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS: The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. Jama. 1990, 263: 1653-1657. 10.1001\/jama.263.12.1653.","journal-title":"Jama"},{"key":"447_CR19","first-page":"24","volume-title":"Epidemiology An introduction","author":"KJ Rothman","year":"2002","unstructured":"Rothman KJ: Measuring disease occurrence and causal effects. Epidemiology An introduction. 2002, USA, Oxford University Press, Chapter 3: 24-56."},{"key":"447_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/jech.46.2.136","volume":"46","author":"RM Herings","year":"1992","unstructured":"Herings RM, Bakker A, Stricker BH, Nap G: Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health. 1992, 46: 136-140.","journal-title":"J Epidemiol Community Health"},{"key":"447_CR21","volume-title":"Utrecht Institute for Pharmaceutical Sciences","author":"RM Herings","year":"1993","unstructured":"Herings RM: PHARMO: A record linkage system for postmarketing surveillance of prescription drugs in the Netherlands. Utrecht Institute for Pharmaceutical Sciences. 1993, Utrecht, Utrecht University"},{"key":"447_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An introduction to the bootstrap","author":"B Efron","year":"1993","unstructured":"Efron B, Tibshirani RJ: An introduction to the bootstrap. 1993, New York, Chapmann & Hall"},{"key":"447_CR23","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","volume":"158","author":"WA Ray","year":"2003","unstructured":"Ray WA: Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003, 158: 915-920. 10.1093\/aje\/kwg231.","journal-title":"Am J Epidemiol"},{"key":"447_CR24","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1097\/01.hjh.0000187261.40190.2e","volume":"23","author":"BL Van Wijk","year":"2005","unstructured":"Van Wijk BL, Klungel OH, Heerdink ER, de Boer A: Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005, 23: 2101-2107. 10.1097\/01.hjh.0000187261.40190.2e.","journal-title":"J Hypertens"},{"key":"447_CR25","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/hrt.2003.026187","volume":"90","author":"AK Mantel-Teeuwisse","year":"2004","unstructured":"Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM: Long term persistence with statin treatment in daily medical practice. Heart. 2004, 90: 1065-1066. 10.1136\/hrt.2003.026187.","journal-title":"Heart"},{"key":"447_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1345\/aph.1C038","volume":"37","author":"ME van der Elst","year":"2003","unstructured":"van der Elst ME, Cisneros-Gonzalez N, de Blaey CJ, Buurma H, de Boer A: Oral antithrombotic use among myocardial infarction patients. Ann Pharmacother. 2003, 37: 143-146. 10.1345\/aph.1C038.","journal-title":"Ann Pharmacother"},{"key":"447_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S1388-9842(02)00256-8","volume":"5","author":"ML Bouvy","year":"2003","unstructured":"Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW: Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. Eur J Heart Fail. 2003, 5: 195-200. 10.1016\/S1388-9842(02)00256-8.","journal-title":"Eur J Heart Fail"},{"key":"447_CR28","first-page":"78","volume":"60","author":"HG Leufkens","year":"2002","unstructured":"Leufkens HG: Pharmacoepidemiological modelling: Markov models of antibiotic use in patients with diabetes. Neth J Med. 2002, 60: 78-82.","journal-title":"Neth J Med"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-7-106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6963-7-106\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-7-106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-7-106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:38:27Z","timestamp":1630463907000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/1472-6963-7-106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,10]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1186\/1472-6963-7-106","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,10]]},"assertion":[{"value":"9 October 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"106"}}